The use of modafinil for the treatment of fatigue in multiple sclerosis: A systematic review and meta-analysis of controlled clinical trials
Source : https://pubmed.ncbi.nlm.nih.gov/38988104/
The data indicates that modafinil confers a therapeutic benefit when treating fatigue in patients with MS and improves overall quality of life; however, there is a risk of precipitating adverse...
Modafinil reduces fatigue in MS patients and improves quality of life, but with increased risk of adverse events. More robust evidence is needed for clinical management.
Application of Theiler's murine encephalomyelitis virus in treatment of multiple sclerosis
Source : https://pubmed.ncbi.nlm.nih.gov/38989030/
Theiler's murine encephalomyelitis virus (TMEV) infected mice have been often used as an animal model for Multiple sclerosis (MS) due to their similar pathology in the central nervous system (CNS)....
The review summarizes drugs tested in the TMEV-induced MS model, aiming to guide treatments and offer theoretical insights for virus-induced multiple sclerosis.
Multiple sclerosis treatment review for primary care providers
Source : https://pubmed.ncbi.nlm.nih.gov/38915149/
The treatment landscape for multiple sclerosis has dramatically grown in terms of available options and complexity. The various mechanisms of action and safety profiles of these new treatments necessitate that...
The treatment landscape for multiple sclerosis has expanded with complex options, requiring primary care providers to stay updated on mechanisms, safety profiles, and practice guidelines for high-quality care.
Role of fenofibrate in multiple sclerosis
Source : https://pubmed.ncbi.nlm.nih.gov/38336772/
Multiple sclerosis (MS) is the most frequent inflammatory and demyelinating disease of the central nervous system (CNS). The underlying pathophysiology of MS is the destruction of myelin sheath by immune...
Fenofibrate mitigates multiple sclerosis neuropathology by modulating oxidative stress, autophagy, mitochondrial dysfunction, inflammatory pathways, and neuroinflammation.
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Source : https://pubmed.ncbi.nlm.nih.gov/38646534/
Multiple Sclerosis (MS) management in individuals aged 55 and above presents unique challenges due to the complex interaction between aging, comorbidities, immunosenescence, and MS pathophysiology. This comprehensive review explores the...
Personalized management of MS in older adults requires comprehensive care, incorporating DMTs, non-pharmacologic approaches, and advance planning, emphasizing patient preferences and continuous monitoring to improve outcomes in this growing patient demographic.